January 17, 2013
SIU Med School Takes Part in Research Study to Treat Critical Limb Ischemia
The Division of Vascular Surgery at Southern Illinois University (SIU) School of Medicine in Springfield is enrolling patients in a multi-site national research study using an investigational cell therapy to treat patients with critical limb ischemia (CLI). In the study, researchers will use cells from a patient’s own aspirated bone marrow to develop a cell therapy to treat CLI. Because it is a randomized trial, patients will have a 50 percent chance of being treated with a placebo or ixmylocel-T, an investigational regenerative medicine developed by Aastrom Biosciences.
“CLI is a severe vascular disease that is unfortunately not correctable in some patients, and their only option is amputation,” said Dr. Douglas Hood, associate professor of vascular surgery and the principal investigator of the trial. “If this trial proves successful, this could lead to a new treatment option for thousands of patients who currently have none.”
The REVIVE study is for patients who have no surgical treatment options to restore blood flow and are facing amputation. Up to 40 percent of all CLI patients are not surgical candidates. REVIVE is the largest randomized, double-blind, placebo-controlled study ever conducted in patients with CLI. The primary endpoint of the trial is amputation-free survival at 12 months.
For more information about participating in the study, call Tiffany at 217-545-2531. For initial screening or for more information, visit www.revivecli.com.